Zacks Research Forecasts Reduced Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Zacks Research cut their Q4 2025 EPS estimates for Zimmer Biomet in a research note issued to investors on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.37 for the quarter, down from their prior forecast of $2.38. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share.

A number of other brokerages have also recently weighed in on ZBH. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. TD Cowen reduced their price target on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. JPMorgan Chase & Co. dropped their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, September 16th. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Finally, UBS Group lowered their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Trading Up 1.2 %

Shares of ZBH stock opened at $112.02 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The stock has a market capitalization of $22.30 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The company has a 50 day moving average price of $107.18 and a 200 day moving average price of $109.50. Zimmer Biomet has a fifty-two week low of $101.47 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the business earned $1.65 earnings per share.

Institutional Investors Weigh In On Zimmer Biomet

Several hedge funds have recently modified their holdings of the business. American Century Companies Inc. grew its holdings in shares of Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares during the period. Van ECK Associates Corp raised its position in shares of Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after purchasing an additional 411,163 shares during the period. Victory Capital Management Inc. raised its position in shares of Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider’s stock worth $365,163,000 after purchasing an additional 211,637 shares during the period. Finally, Boston Partners raised its position in Zimmer Biomet by 26.3% in the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after buying an additional 691,191 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.